NZ331647A - Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives - Google Patents

Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives

Info

Publication number
NZ331647A
NZ331647A NZ331647A NZ33164797A NZ331647A NZ 331647 A NZ331647 A NZ 331647A NZ 331647 A NZ331647 A NZ 331647A NZ 33164797 A NZ33164797 A NZ 33164797A NZ 331647 A NZ331647 A NZ 331647A
Authority
NZ
New Zealand
Prior art keywords
nr9cor10
haloalkyl
halo
alkyl
disorder
Prior art date
Application number
NZ331647A
Inventor
Parthasarathi Rajagopalan
Robert John Chorvat
Rajagopal Bakthavatchalam
James Peter Beck
Paul Joseph Gilligan
Richard Eric Olson
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of NZ331647A publication Critical patent/NZ331647A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A CRF antagonist of the formula 1 or II where X is N or CR1 Y is N or CR2 Z is NR3, O or S(O)n G is O or S Q is O or S(O)n n is 1or 2 Ar is phenyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, furanly, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzthiazolyl, isoxazolyl or pyrazolyl each optionally substituted with 1-4 R5 groups which is defined in the specification R1 is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, C1-4 haloalkyl, -NR9R10, NR9COR10, OR11, SH or -S(O)nR12 R2 is H, C1-4 alkyl, C1-6 cycloalkyl, halo, CN, -NR6R7, NR9COR10, C1-4 haloalkyl, -OR7, SH or -S(O)nR12. R9, R10, R6, R7, R11 and R12 are defined in the specification. Further claimed is the use of these compounds for treating affective disorder, anxiety, depression, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal disease, anorexia and other feeding disorders, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorder or fertility problems.
NZ331647A 1996-03-26 1997-03-25 Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives NZ331647A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1409096P 1996-03-26 1996-03-26
US64661196A 1996-05-08 1996-05-08
PCT/US1997/004828 WO1997035846A1 (en) 1996-03-26 1997-03-25 Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives

Publications (1)

Publication Number Publication Date
NZ331647A true NZ331647A (en) 2000-03-27

Family

ID=26685647

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ331647A NZ331647A (en) 1996-03-26 1997-03-25 Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives

Country Status (6)

Country Link
EP (1) EP0901476A4 (en)
JP (1) JP2000507552A (en)
AU (1) AU725254B2 (en)
CA (1) CA2249598A1 (en)
NZ (1) NZ331647A (en)
WO (1) WO1997035846A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19653646A1 (en) * 1996-12-20 1998-06-25 Hoechst Ag Substituted purine derivatives, processes for their preparation, agents containing them and their use
PT1129091E (en) 1998-11-12 2003-02-28 Neurocrine Biosciences Inc CRF RECEIVER ANTAGONISTS AND RELATED METHODS
CN1178941C (en) 1998-11-12 2004-12-08 纽罗克里恩生物科学有限公司 CRF receptor antagonists and methods relating thereto
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
EP1301511A2 (en) * 2000-07-14 2003-04-16 Bristol-Myers Squibb Pharma Company IMIDAZO 1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
HU229317B1 (en) 2001-03-13 2013-10-28 Bristol Myers Squibb Pharma Co 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine derivatives, and enantiomers of the same az cortikotropine releasing factor (cfr) ligands
RU2003135424A (en) 2001-05-14 2005-05-20 Бристол-Маерс Сквибб Фарма Компани (Us) SUBSTITUTED PYRAZINONES, PYRIDINES AND PYRIMIDINES AS LIGANDS OF CORTICOTROPINE RELAXING FACTOR
WO2003005969A2 (en) 2001-07-12 2003-01-23 Bristol-Myers Squibb Pharma Company Tetrahydropurinones as corticotropin releasing factor
WO2003006015A1 (en) 2001-07-13 2003-01-23 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
AU2002340405A1 (en) 2001-11-20 2003-06-10 Bristol-Myers Squibb Pharma Company 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
KR20210061202A (en) * 2019-11-19 2021-05-27 일동제약(주) Benzonitrile-substituted Fused pyrimidine derivatives and their pharmaceutical use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4076711A (en) * 1976-04-05 1978-02-28 Schering Corporation Triazolo [4,5-d]-pyrimidines
JPS56131586A (en) * 1980-03-18 1981-10-15 Ss Pharmaceut Co Ltd Triazolopyrimidine derivative and its preparation
JPS56131587A (en) * 1980-03-18 1981-10-15 Ss Pharmaceut Co Ltd 7-substituted triazolopyrimidine derivative and its preparation
JPS5962595A (en) * 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd 3,5,7-trisubstituted-triazolopyrimidine derivative and its preparation
EP0141927B1 (en) * 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
DE3722802A1 (en) * 1987-07-10 1989-01-19 Hoechst Ag 2-AMINO-8-AZA PURINS SUBSTITUTED IN 6 AND 9 POSITIONS, THEIR USE, MEDICINAL PRODUCTS CONTAINING THESE PURINES AND METHOD FOR THE PRODUCTION OF THE PURINS
US4916224A (en) * 1988-01-20 1990-04-10 Regents Of The University Of Minnesota Dideoxycarbocyclic nucleosides
GB9011623D0 (en) * 1990-05-24 1990-07-11 Efamol Holdings Synthesis of nucleotide and nucleoside derivatives
KR19990067704A (en) * 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 Pharmaceutical composition containing pyrrolopyrimidine as an adrenal cortical stimulating hormone free factor antagonist
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
CN1142817A (en) * 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
GB9400987D0 (en) * 1994-01-19 1994-03-16 Reese Colin B Production of nucleoside analogues
EP0764153A1 (en) * 1994-06-06 1997-03-26 Pfizer Inc. Substituted pyrazoles having corticotropin-releasing factor (crf) antagonist activity
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
JP2891544B2 (en) * 1994-06-16 1999-05-17 ファイザー・インコーポレーテッド Pyrazolo and pyrrolopyridines
DK0778277T3 (en) * 1995-12-08 2003-10-27 Pfizer Substituted heterocyclic derivatives as CRF antagonists

Also Published As

Publication number Publication date
WO1997035846A1 (en) 1997-10-02
JP2000507552A (en) 2000-06-20
AU725254B2 (en) 2000-10-12
AU2545397A (en) 1997-10-17
CA2249598A1 (en) 1997-10-02
EP0901476A1 (en) 1999-03-17
EP0901476A4 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
NZ331647A (en) Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
AU2006337626B2 (en) [4-(benzo [b] thiophen-2-yl) pyrimidin-2yl] -amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases.
WO2002098852A8 (en) Novel benzothienyl or indole derivatives, and use thereof as inhibitors of prenyl transferase proteins
GR3026231T3 (en) 3-aminopiperidine derivatives and related nitrogen containing heterocycles.
ES2299826T3 (en) PIRIMIDIN-2-ONA COMPOUNDS AND ITS USE AS LEGANDS OF THE DOPAMINE DE3 RECEIVER.
NZ332704A (en) 8-(substituted phenyl)-tetrahydropteridines and pyridylpiperazines useful in the treatment of neurological disorders
US7229995B2 (en) Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
EA199800907A1 (en) DERIVATIVES OF CARBOLINE
AU2003226553A1 (en) Inhibitors of histone deacetylase
CA2428844A1 (en) Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
NZ331319A (en) Cyclic amine derivatives that are CCR-3 receptor (chemokine receptor) antagonists, compositions containing them and methods for their use (to combat eosinophil induced diseases).
DE69130869D1 (en) Xanthinderivate
RS50444B (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
DE69232588D1 (en) Condensed tricyclic, nitrogen-containing compounds as substance P receptor antagonists
BR0201087A (en) Benzotriazole anti-inflammatory compounds
Secrist III et al. Studies directed toward a total synthesis of nucleoside Q. Annulation of 2, 6-diaminopyrimidin-4-one with. alpha.-halo carbonyls to form pyrrolo [2, 3-d] pyrimidines and furo [2, 3-d] pyrimidines
ES366910A1 (en) A procedure for preparing 1-glycosil-5-azacitosines. (Machine-translation by Google Translate, not legally binding)
US6958349B2 (en) Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
MXPA04002495A (en) Imidazopyridine compounds as 5-ht4.
CO4990959A1 (en) ISOQUINOLINS
MA21030A1 (en) BENZHYDRYLOXYETHYL-PIPERAZINE DERIVATIVES AND PROCESS FOR OBTAINING THE SAME.
DE69022744D1 (en) PIPERIDINE AND PYRROLIDINE DERIVATIVES.
NZ331646A (en) Aryloxy- and arylthio-substituted pyrimidines and triazines and derivatives thereof
FR2735128B1 (en) NOVEL BENZENESULFONAMIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USE.
DE69013672D1 (en) HALOGEN-SUBSTITUTED AMINOTETRALINE.